Literature DB >> 20859804

Methylxanthines during pregnancy and early postnatal life.

Ulrika Adén1.   

Abstract

World-wide, many fetuses and infants are exposed to methylxanthines via maternal consumption of coffee and other beverages containing these substances. Methylxanthines (caffeine, theophylline and aminophylline) are also commonly used as a medication for apnea of prematurity.The metabolism of methylxanthines is impaired in pregnant women, fetuses and neonates, leading to accumulating levels thereof. Methylxanthines readily passes the placenta barrier and enters all tissues and thus may affect the fetus/newborn at any time during pregnancy or postnatal life, given that the effector systems are mature.At clinically relevant doses, the major effector system for methylxanthines is adenosine receptors. Animal studies suggest that adenosine receptors in the cardiovascular, respiratory and immune system are developed at birth, but that cerebral adenosine receptors are not fully functional. Furthermore animal studies have shown protective positive effects of methylxanthines in situations of hypoxia/ischemia in neonates. Similarly, a positive long-term effect on lung function and CNS development was found in human preterm infants treated with high doses of caffeine for apneas. There is now evidence that the overall benefits from methylxanthine therapy for apnea of prematurity outweigh potential short-term risks.On the other hand it is important to note that experimental studies have indicated that long-term effects of caffeine during pregnancy and postnatally may include altered behavior and altered respiratory control in the offspring, although there is currently no human data to support this.Some epidemiology studies have reported negative effects on pregnancy and perinatal outcomes related to maternal ingestion of high doses of caffeine, but the results are inconclusive. The evidence base for adverse effects of caffeine in first third of pregnancy are stronger than for later parts of pregnancy and there is currently insufficient evidence to advise women to restrict caffeine intake after the first trimester.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20859804     DOI: 10.1007/978-3-642-13443-2_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  15 in total

1.  Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver.

Authors:  Barent DuBois; Samantha Louey; George D Giraud; Ganesh Cherala; Sonnet S Jonker
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-03-19       Impact factor: 4.080

Review 2.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

3.  Behavioral profile assessment in offspring of Swiss mice treated during pregnancy and lactation with caffeine.

Authors:  Roberto Laureano-Melo; Anderson Luiz Bezerra da Silveira; Fernando de Azevedo Cruz Seara; Rodrigo Rodrigues da Conceição; Cláudio da Silva-Almeida; Bruno Guimarães Marinho; Fábio Fagundes da Rocha; Luís Carlos Reis; Wellington da Silva Côrtes
Journal:  Metab Brain Dis       Date:  2016-06-04       Impact factor: 3.584

Review 4.  Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.

Authors:  Katherine Schoen; Tian Yu; Chris Stockmann; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.022

5.  Caffeine inhibits hypoxia-induced nuclear accumulation in HIF-1α and promotes neonatal neuronal survival.

Authors:  Hsiu-Ling Li; Nahla Zaghloul; Ijaz Ahmed; Anton Omelchenko; Bonnie L Firestein; Hai Huang; Latoya Collins
Journal:  Exp Neurol       Date:  2019-02-26       Impact factor: 5.330

Review 6.  Apnea of prematurity: from cause to treatment.

Authors:  Jing Zhao; Fernando Gonzalez; Dezhi Mu
Journal:  Eur J Pediatr       Date:  2011-02-08       Impact factor: 3.183

7.  Caffeine acts via A1 adenosine receptors to disrupt embryonic cardiac function.

Authors:  Daniela L Buscariollo; Gregory A Breuer; Christopher C Wendler; Scott A Rivkees
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

8.  Single Dose Caffeine Protects the Neonatal Mouse Brain against Hypoxia Ischemia.

Authors:  Max Winerdal; Vijay Urmaliya; Malin E Winerdal; Bertil B Fredholm; Ola Winqvist; Ulrika Ådén
Journal:  PLoS One       Date:  2017-01-27       Impact factor: 3.240

9.  Risky substance exposure during pregnancy: a pilot study from Lebanese mothers.

Authors:  Samar Rachidi; Sanaa Awada; Amal Al-Hajje; Wafaa Bawab; Salam Zein; Nadine Saleh; Pascale Salameh
Journal:  Drug Healthc Patient Saf       Date:  2013-05-15

10.  Therapeutic effect of caffeine treatment immediately following neonatal hypoxic-ischemic injury on spatial memory in male rats.

Authors:  Michelle Alexander; Amanda L Smith; Ted S Rosenkrantz; R Holly Fitch
Journal:  Brain Sci       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.